129 related articles for article (PubMed ID: 9447396)
1. Analysis of screening data: colorectal cancer.
Gyrd-Hansen D; Søgaard J; Kronborg O
Int J Epidemiol; 1997 Dec; 26(6):1172-81. PubMed ID: 9447396
[TBL] [Abstract][Full Text] [Related]
2. Estimation of screening test (Hemoccult) sensitivity in colorectal cancer mass screening.
Jouve JL; Remontet L; Dancourt V; Lejeune C; Benhamiche AM; Faivre J; Esteve J
Br J Cancer; 2001 Jun; 84(11):1477-81. PubMed ID: 11384097
[TBL] [Abstract][Full Text] [Related]
3. Colorectal cancer screening: efficiency and effectiveness.
Gyrd-Hansen D; Søgaard J; Kronborg O
Health Econ; 1998 Feb; 7(1):9-20. PubMed ID: 9541080
[TBL] [Abstract][Full Text] [Related]
4. Estimating age group-dependent sensitivity and mean sojourn time in colorectal cancer screening.
Sung NY; Jun JK; Kim YN; Jung I; Park S; Kim GR; Nam CM
J Med Screen; 2019 Mar; 26(1):19-25. PubMed ID: 30261804
[TBL] [Abstract][Full Text] [Related]
5. Estimating sensitivity and sojourn time in screening for colorectal cancer: a comparison of statistical approaches.
Prevost TC; Launoy G; Duffy SW; Chen HH
Am J Epidemiol; 1998 Sep; 148(6):609-19. PubMed ID: 9753016
[TBL] [Abstract][Full Text] [Related]
6. Estimated mean sojourn time associated with hemoccult SENSA for detection of proximal and distal colorectal cancer.
Zheng W; Rutter CM
Cancer Epidemiol Biomarkers Prev; 2012 Oct; 21(10):1722-30. PubMed ID: 22911331
[TBL] [Abstract][Full Text] [Related]
7. Colorectal cancer mass-screening: estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time.
Launoy G; Smith TC; Duffy SW; Bouvier V
Int J Cancer; 1997 Oct; 73(2):220-4. PubMed ID: 9335446
[TBL] [Abstract][Full Text] [Related]
8. A simulation model for evaluating the medical and economic outcomes of screening strategies for colorectal cancer.
Lejeune C; Arveux P; Dancourt V; Fagnani F; Bonithon-Kopp C; Faivre J
Eur J Cancer Prev; 2003 Feb; 12(1):77-84. PubMed ID: 12548114
[TBL] [Abstract][Full Text] [Related]
9. A comparison of fecal occult-blood tests for colorectal-cancer screening.
Allison JE; Tekawa IS; Ransom LJ; Adrain AL
N Engl J Med; 1996 Jan; 334(3):155-9. PubMed ID: 8531970
[TBL] [Abstract][Full Text] [Related]
10. Predicting the effectiveness of the Finnish population-based colorectal cancer screening programme.
Chiu SY; Malila N; Yen AM; Chen SL; Fann JC; Hakama M
J Med Screen; 2017 Dec; 24(4):182-188. PubMed ID: 28084889
[TBL] [Abstract][Full Text] [Related]
11. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
Blom J; Törnberg S
J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
[TBL] [Abstract][Full Text] [Related]
12. Is it reasonable to use faecal occult blood test for colorectal cancer screening?
Musil D; Tillich J
Acta Univ Palacki Olomuc Fac Med; 1999; 142():119-21. PubMed ID: 10743740
[TBL] [Abstract][Full Text] [Related]
13. Hemoccult screening in detecting colorectal neoplasm: sensitivity, specificity, and predictive value. Long-term follow-up in a large group practice setting.
Allison JE; Feldman R; Tekawa IS
Ann Intern Med; 1990 Mar; 112(5):328-33. PubMed ID: 2407166
[TBL] [Abstract][Full Text] [Related]
14. Fecal occult blood screening in the Minnesota study: sensitivity of the screening test.
Church TR; Ederer F; Mandel JS
J Natl Cancer Inst; 1997 Oct; 89(19):1440-8. PubMed ID: 9326913
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests.
Ahlquist DA; Wieand HS; Moertel CG; McGill DB; Loprinzi CL; O'Connell MJ; Mailliard JA; Gerstner JB; Pandya K; Ellefson RD
JAMA; 1993 Mar; 269(10):1262-7. PubMed ID: 8437303
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Colorectal Cancer Screening in Detecting Earlier-Stage Disease-A Nationwide Cohort Study in Denmark.
Larsen MB; Njor S; Ingeholm P; Andersen B
Gastroenterology; 2018 Jul; 155(1):99-106. PubMed ID: 29626451
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of latex agglutination faecal occult blood test in the Florence District population-based colorectal cancer screening programme.
Castiglione G; Visioli CB; Ciatto S; Grazzini G; Bonanomi AG; Rubeca T; Mantellini P; Zappa M
Br J Cancer; 2007 Jun; 96(11):1750-4. PubMed ID: 17453007
[TBL] [Abstract][Full Text] [Related]
18. Causes of death during the first 5 years of a randomized trial of mass screening for colorectal cancer with fecal occult blood test.
Kronborg O; Fenger C; Worm J; Pedersen SA; Hem J; Bertelsen K; Olsen J
Scand J Gastroenterol; 1992; 27(1):47-52. PubMed ID: 1736342
[TBL] [Abstract][Full Text] [Related]
19. Fecal occult blood testing: clinical value and limitations.
Simon JB
Gastroenterologist; 1998 Mar; 6(1):66-78. PubMed ID: 9531118
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
